Pathways for aberrant angiogenesis in pancreatic cancer

Murray Korc

Research output: Contribution to journalArticle

135 Citations (Scopus)

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease. Although the specific mechanisms that dictate its biological aggressiveness are not clearly established, it is characterized by a variety of molecular alterations as well as by the overexpression of mitogenic and angiogenic growth factors and their receptors. PDACs also express high levels of vascular endothelial growth factor (VEGF). Recent studies indicate that suppression of VEGF expression attenuates pancreatic cancer cell tumorigenicity in a nude mouse model, and that VEGF can exert direct mitogenic effects on some pancreatic cancer cells. These findings suggest that cancer cell derived VEGF promotes pancreatic cancer growth in vivo via a paracrine angiogenic pathway and an autocrine mitogenic pathway, and provide novel opportunities for therapeutic intervention in this deadly disease.

Original languageEnglish (US)
Article number8
JournalMolecular Cancer
Volume2
DOIs
StatePublished - Jan 7 2003
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Vascular Endothelial Growth Factor A
Cells
Growth Factor Receptors
Angiogenesis Inducing Agents
Nude Mice
Adenocarcinoma
Growth
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)
  • Cancer Research
  • Molecular Medicine

Cite this

Pathways for aberrant angiogenesis in pancreatic cancer. / Korc, Murray.

In: Molecular Cancer, Vol. 2, 8, 07.01.2003.

Research output: Contribution to journalArticle

@article{c7d44bfcbc5d4dd39890a29501ae74ee,
title = "Pathways for aberrant angiogenesis in pancreatic cancer",
abstract = "Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease. Although the specific mechanisms that dictate its biological aggressiveness are not clearly established, it is characterized by a variety of molecular alterations as well as by the overexpression of mitogenic and angiogenic growth factors and their receptors. PDACs also express high levels of vascular endothelial growth factor (VEGF). Recent studies indicate that suppression of VEGF expression attenuates pancreatic cancer cell tumorigenicity in a nude mouse model, and that VEGF can exert direct mitogenic effects on some pancreatic cancer cells. These findings suggest that cancer cell derived VEGF promotes pancreatic cancer growth in vivo via a paracrine angiogenic pathway and an autocrine mitogenic pathway, and provide novel opportunities for therapeutic intervention in this deadly disease.",
author = "Murray Korc",
year = "2003",
month = "1",
day = "7",
doi = "10.1186/1476-4598-2-8",
language = "English (US)",
volume = "2",
journal = "Molecular Cancer",
issn = "1476-4598",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Pathways for aberrant angiogenesis in pancreatic cancer

AU - Korc, Murray

PY - 2003/1/7

Y1 - 2003/1/7

N2 - Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease. Although the specific mechanisms that dictate its biological aggressiveness are not clearly established, it is characterized by a variety of molecular alterations as well as by the overexpression of mitogenic and angiogenic growth factors and their receptors. PDACs also express high levels of vascular endothelial growth factor (VEGF). Recent studies indicate that suppression of VEGF expression attenuates pancreatic cancer cell tumorigenicity in a nude mouse model, and that VEGF can exert direct mitogenic effects on some pancreatic cancer cells. These findings suggest that cancer cell derived VEGF promotes pancreatic cancer growth in vivo via a paracrine angiogenic pathway and an autocrine mitogenic pathway, and provide novel opportunities for therapeutic intervention in this deadly disease.

AB - Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease. Although the specific mechanisms that dictate its biological aggressiveness are not clearly established, it is characterized by a variety of molecular alterations as well as by the overexpression of mitogenic and angiogenic growth factors and their receptors. PDACs also express high levels of vascular endothelial growth factor (VEGF). Recent studies indicate that suppression of VEGF expression attenuates pancreatic cancer cell tumorigenicity in a nude mouse model, and that VEGF can exert direct mitogenic effects on some pancreatic cancer cells. These findings suggest that cancer cell derived VEGF promotes pancreatic cancer growth in vivo via a paracrine angiogenic pathway and an autocrine mitogenic pathway, and provide novel opportunities for therapeutic intervention in this deadly disease.

UR - http://www.scopus.com/inward/record.url?scp=2542471865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2542471865&partnerID=8YFLogxK

U2 - 10.1186/1476-4598-2-8

DO - 10.1186/1476-4598-2-8

M3 - Article

C2 - 12556241

AN - SCOPUS:2542471865

VL - 2

JO - Molecular Cancer

JF - Molecular Cancer

SN - 1476-4598

M1 - 8

ER -